ClinicalTrials.Veeva

Menu

Urinary Biomarkers for AKI Diagnosis in Patients With SARS-CoV-2 (COVID-19) (COVID-AKI)

University Hospital Center (CHU) logo

University Hospital Center (CHU)

Status

Completed

Conditions

COVID-19
Renal Replacement Therapy
Acute Kidney Injury

Treatments

Other: [TIMP-2]*[IGFBP-7]

Study type

Observational

Funder types

Other

Identifiers

NCT04393428
RECHMPL20_0294

Details and patient eligibility

About

Among patients with SARS-CoV-2 pneumonia, approximately 20% have an acute kidney injury (AKI) and 5% require renal replacement therapy. Occurrence of AKI in patients with COVID-19 is associated with increased morbidity and mortality. Early detection of patients at risk of AKI would allow to prevent onset or worsening of AKI. The aim of this study is to determine if urine biomarkers of renal tubular damage such as TIMP-2 and IGFBP7 could early identify patients with SARS-CoV-2 pneumonia at risk of developing AKI.

Enrollment

100 patients

Sex

All

Ages

18 to 100 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Age ≥ 18 years
  • COVID-19 confirmed by positive SARS-CoV-2 PCR
  • at least one urine sample

Exclusion criteria

  • Persons under protection
  • Paritcipation rejections

Trial design

100 participants in 1 patient group

COVID-19 patients with urinary samples
Description:
COVID-19 patients with urinary samples
Treatment:
Other: [TIMP-2]*[IGFBP-7]

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems